Mainstream

Y-mAbs Therapeutics beats top-line and bottom-line estimates; initiates Q2 and reaffirms FY outlook

Y-mAbs Therapeutics beats top-line and bottom-line estimates; initiates Q2 and reaffirms FY outlook

Post ContentymabRead More

You might also be interested in reading Arthur Hayes’ New Private Equity Fund Focuses on ‘Picks and Shovels’ of Crypto.

May 13, 2025
In Mainstream